News and Trends 30 Mar 2023 Could new riboswitch make gene therapy safer? Turning genes on and off as easily and predictably as flicking a switch could be a powerful tool in medicine and biotech. A type of technology called a riboswitch might be the key.The Okinawa Institute of Science and Technology (OIST) in Japan, in collaboration with Astellas Pharma Inc., has developed a new toolkit that uses […] March 30, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 SR One closes biotech fund at $600M SR One, a transatlantic life sciences investment firm, has announced the close of its second fund at more than $600 million, exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm. The diverse investor base of […] March 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2023 Pharming immunodeficiency drug given FDA approval Pharming Group N.V. has announced that the US Food and Drug Administration (FDA) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Pharming’s Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the […] March 29, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Mar 2023 5 hearing loss biotech companies you should know about More than 1.5 billion people – nearly 20% of the world’s population – live with hearing loss globally, with 430 million suffering from disabling hearing loss. In this article, we take a look at five of the top hearing loss companies making efforts to reduce these figures. According to the World Health Organization (WHO), nearly […] March 29, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Inside Labiotech 28 Mar 2023 Noticed something different? Labiotech is getting a new look for 2023! Hi there, dear readers! I know, it’s been a while since we posted “behind the scene” updates from Labiotech so I’m sure you’re curious to know what we’ve been cooking during the past few months. Well, the reason is simple, we’ve been working hard on a whole new design for the website! With this new […] March 28, 2023 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
Infographics by Merck 28 Mar 2023 Infographic: Why choosing a client-centric CTDMO is critical when outsourcing biomanufacturing projects In 2021, 28% of FDA approvals were granted to biologic drugs, showcasing the increasing demand for the biopharma industry to develop, manufacture and market biologic-based therapies. Biologic drugs include monoclonal antibodies and large molecules produced in mammalian cells, bringing the already complex process of drug development to a new level. Although the biomanufacturing of many […] March 28, 2023 - 2 minutesmins - By Maya Chergova Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023Beyond Biotech podcast 39: World Tuberculosis Day March 24 is World Tuberculosis Day. To mark the occasion, we have conversations with Christopher Fox, senior vice president, formulations, at the Access to Advanced Health Institute; TB Alliance CEO Mel Spigelman; and Jane Theaker, CEO of PBD Biotech. This episode of the podcast is sponsored by Samplix. World Tuberculosis Day Tuberculosis is a leading […] March 24, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Evotec receives $6.6M for tuberculosis drug discovery On World Tuberculosis Day, Evotec SE has announced that it has received a $ 6.6 million grant from The Bill & Melinda Gates Foundation for drug discovery to tackle tuberculosis. The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the company to progress a portfolio of TB […] March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Metabolism of RNA linked to leukemia Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits in cancer. RNA splicing is […] March 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Microbiome therapeutics biotech mbiomics raises €13M mbiomics GmbH, a German microbiome biotech company developing the first generation of effective microbiome-based therapeutics has closed €13 million ($ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors. mbiomics uses its proprietary, tailored high-resolution […] March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 24 Mar 2023 PAN-TB regimens to address growing TB drug resistance By Dr. Charles Wells, head of therapeutics development at Gates Medical Research Institute As nearly one-quarter of the world’s population is presumed to be infected with Mycobacterium tuberculosis bacteria and are at risk for developing active tuberculosis (TB), the disease represents a major public health challenge globally. As reported by the World Health Organization (WHO), […] March 24, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 OncoC4 and BioNTech partner in the commercialization of cancer drug candidate German biopharma BioNTech has closed a licensing deal with the U.S.-based clinical-stage company OncoC4 for the development and commercialization of the latter’s lead candidate ONC-392, for the treatment of cancer. OncoC4 will receive $200 million upfront, and the transaction is expected to be completed in the first half of 2023. The company will also be […] March 23, 2023 - 2 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email